We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

396 hedge funds and large institutions have $2.2B invested in CRISPR Therapeutics in 2025 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 123 increasing their positions, 102 reducing their positions, and 59 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

27% more call options, than puts

Call options by funds: $96.3M | Put options by funds: $75.6M

21% more repeat investments, than reductions

Existing positions increased: 123 | Existing positions reduced: 102

0.25% less ownership

Funds ownership: 75.64% → 75.39% (-0.25%)

7% less first-time investments, than exits

New positions opened: 55 | Existing positions closed: 59

2% less funds holding

Funds holding: 404 → 396 (-8)

13% less capital invested

Capital invested by funds: $2.54B → $2.2B (-$339M)

Holders
396
Holders Change
-8
Holders Change %
-1.98%
% of All Funds
5.31%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
55
Increased
123
Reduced
102
Closed
59
Calls
$96.3M
Puts
$75.6M
Net Calls
+$20.7M
Net Calls Change
+$30.7M

Top Buyers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
+$53.5M
2
AIM
ARK Investment Management
Florida
+$50.5M
3
Two Sigma Investments
Two Sigma Investments
New York
+$37.4M
4
Morgan Stanley
Morgan Stanley
New York
+$34.1M
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$30.2M

Top Sellers

Rank Fund Capital Flow
1
Capital International Investors
Capital International Investors
California
-$113M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$34.4M
3
BBA
Baker Bros. Advisors
New York
-$27.7M
4
Citadel Advisors
Citadel Advisors
Florida
-$26.3M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$12M
Name Holding Trade Value Shares
Change 		Change in
Stake
Voloridge Investment Management
401
Voloridge Investment Management
Florida
– -$2.08M -52,835 Closed
Thrivent Financial for Lutherans
402
Thrivent Financial for Lutherans
Minnesota
– -$1.69M -42,887 Closed
WFI
403
West Family Investments
California
– -$1.4M -35,500 Closed
Schroder Investment Management Group
404
Schroder Investment Management Group
United Kingdom
– -$889K -23,000 Closed
IAS
405
IMA Advisory Services
Colorado
– -$778K -19,776 Closed
Capital Fund Management (CFM)
406
Capital Fund Management (CFM)
France
– -$767K -18,097 Closed
QCM
407
Qsemble Capital Management
New York
– -$695K -17,664 Closed
HSBC Holdings
408
HSBC Holdings
United Kingdom
– -$685K -17,496 Closed
NIM
409
NEOS Investment Management
Connecticut
– -$639K -16,231 Closed
ETC
410
Exchange Traded Concepts
Oklahoma
– -$635K -16,127 Closed
PCM
411
Prelude Capital Management
New York
– -$590K -15,000 Closed
FIA
412
FNY Investment Advisers
New York
– -$413K -10,500 Closed
MF
413
Magnetar Financial
Illinois
– -$359K -9,125 Closed
Corient Private Wealth
414
Corient Private Wealth
Florida
– -$347K -8,827 Closed
YC
415
Yarbrough Capital
Tennessee
– -$331K -8,399 Closed
VEA
416
Virtus ETF Advisers
New York
– -$303K -7,702 Closed
MCP
417
Mirador Capital Partners
California
– -$297K -7,536 Closed
DTL
418
Dynamic Technology Lab
Singapore
– -$285K -7,230 Closed
IP
419
Intellectus Partners
California
– -$281K -7,131 Closed
FCM
420
Fieldview Capital Management
Michigan
– -$270K -6,857 Closed
GCA
421
Greenwood Capital Associates
South Carolina
– -$265K -6,733 Closed
VFA
422
Valeo Financial Advisors
Indiana
– -$250K -6,358 Closed
ACA
423
Aptus Capital Advisors
Alabama
– -$248K -6,298 Closed
JG
424
Jain Global
New York
– -$242K -6,155 Closed
Focus Partners Wealth
425
Focus Partners Wealth
Massachusetts
– -$239K -6,082 Closed
15 16
17
18 19

CRSP Hedge Fund Activity: Q1 2025 in Review

396 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q1 2025, worth a combined $2.2B — down 13% from $2.54B a quarter earlier.

Sellers outnumbered buyers: 59 funds closed out of CRSP and 55 opened new positions — a net loss of 4 holders — while 102 trimmed existing stakes and 123 added.

The largest buyer was UBS AM, adding an estimated $53.5M. The largest seller was Capital International Investors, cutting an estimated $113M.

  • 396 institutional investors held CRISPR Therapeutics (CRSP) as of Q1 2025, down from 404 in Q4 2024.
  • Funds reported $2.2B of CRISPR Therapeutics stock for Q1 2025, down 13% quarter-over-quarter.
  • 55 funds opened new CRISPR Therapeutics positions in Q1 2025 and 59 closed out, a net change of -4 holders.
  • The largest CRISPR Therapeutics buyer in Q1 2025 was UBS AM, an estimated $53.5M added.
  • The largest CRISPR Therapeutics seller in Q1 2025 was Capital International Investors, an estimated $113M sold.

Based on aggregated 13F filings for Q1 2025.